Newswise — Durham, N.C. (Aug. 10, 2021) – A study led by the Duke Clinical Research Institute has expanded its testing platform to evaluate three repurposed medications in the search for effective, safe treatments for mild-to-moderate COVID-19. Repurposed medications are those already approved by the U.S. Food and Drug Administration for other indications.
“We have treatments for people with severe COVID-19 who are at high risk for hospitalization or death, but they are complex to administer,” said Adrian Hernandez, M.D., the study’s administrative principal investigator and executive director of the DCRI. “Currently, there are no approved prescription medications that can be easily given at home to treat mild-to-moderate symptoms of the virus early in its course to prevent worsening of COVID-19.”
ACTIV-6, “The Randomized Trial to Evaluate Efficacy of Repurposed Medications,” is a nationwide double-blind study expected to enroll nearly 15,000 participants from across the United States through its website, https://activ6study.org, and call center, 833-385-1880. The study is now testing these repurposed medications:
- Ivermectin, used to treat parasitic infections;
- Fluticasone, an inhaled steroid commonly prescribed for asthma and chronic obstructive pulmonary disease; and
- Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), often prescribed for depression.
Hernandez noted the study will continue to add medications over time. “The medications studied in ACTIV-6 have shown potential for treating COVID-19 in the outpatient setting, but they need to be evaluated in a larger, more rigorous and randomized clinical trial to determine efficacy and safety,” he said.
To be eligible, participants must be 30 years old or older, have had a positive COVID-19 test within the past 10 days, and have at least two symptoms of the illness for seven days or less. Symptoms include fatigue, difficulty breathing, fever, cough, nausea, vomiting, diarrhea, body aches, chills, headache, sore throat, nasal symptoms, and/or new loss of sense of taste or smell.
People can participate from anywhere in the United States, and medications are shipped at no cost. Participation involves taking the medication and keeping track of symptoms over 90 days through online surveys.
“Speeding enrollment in the ACTIV-6 study is of critical importance as the pandemic evolves and highly transmissible variants appear throughout the nation and around the world,” said Susanna Naggie, M.D., the DCRI principal investigator overseeing the coordinating center. “The study will yield valuable data on whether repurposed medications can help address the unmet public health need for people experiencing mild-to-moderate COVID-19 symptoms.”
The study is part of the National Institutes of Health-funded Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) led by the National Center for Advancing Translational Sciences. The DCRI serves as the study’s coordinating center, partnering with Vanderbilt University Medical Center as the study’s data coordinating center.
The study is leveraging the infrastructure of PCORnet®, the National Patient-Centered Clinical Research Network, supported by the Patient-Centered Outcomes Research Institute, and the Trial Innovation Network, a collaborative initiative within the NCATS Clinical and Translational Science Awards Program that helps address critical roadblocks in clinical trials and accelerate the translation of novel interventions into life-saving therapies.
# # #
About the Duke Clinical Research Institute
The DCRI, part of the Duke University School of Medicine, is the largest academic clinical research organization in the world. Our mission is to develop, share, and implement knowledge that improves global health through innovative clinical research. The institute conducts multinational clinical trials, manages major national patient registries, and performs landmark outcomes research. The DCRI is a pioneer in cardiovascular and pediatric clinical research, and conducts groundbreaking clinical research across multiple other therapeutic areas, including infectious disease, neuroscience, respiratory medicine, and nephrology. The DCRI is also involved with ACTIV studies, serving as the U.S. coordinating center for ACTIV-1, a COVID-19 master protocol study testing immune modulators, and participating in ACTIV-4, which is examining optimal use of oral anticoagulants to prevent COVID-19-associated blood clots. The DCRI also serves as the coordinating center for major clinical research programs, such as the Environmental Influences On Child Health (ECHO) program, the Antibacterial Resistance Leadership Group (ARLG), the NIH Health Care Systems Research Collaboratory, and the Pediatric Trials Network (PTN).